Chronic myelogenous leukemia epidemiology and demographics: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Chronic myelogenous leukemia}} | {{Chronic myelogenous leukemia}} | ||
{{CMG}} | {{CMG}} | ||
Revision as of 15:10, 11 September 2012
|
Chronic myelogenous leukemia Microchapters |
|
Differentiating Chronic myelogenous leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic myelogenous leukemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Chronic myelogenous leukemia epidemiology and demographics |
|
FDA on Chronic myelogenous leukemia epidemiology and demographics |
|
CDC on Chronic myelogenous leukemia epidemiology and demographics |
|
Chronic myelogenous leukemia epidemiology and demographics in the news |
|
Blogs on Chronic myelogenous leukemia epidemiology and demographics |
|
Directions to Hospitals Treating Chronic myelogenous leukemia |
|
Risk calculators and risk factors for Chronic myelogenous leukemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Epidemiology
CML occurs in all age groups, but most commonly in the middle-aged and elderly. Its annual incidence is 1–2 per 100,000 people, and slightly more men than women are affected. CML represents about 15–20% of all cases of adult leukemia in Western populations.[1] The only well-described risk factor for CML is exposure to ionizing radiation; for example, increased rates of CML were seen in people exposed to the atomic bombings of Hiroshima and Nagasaki.[2]